PTTG1-driven self-amplifying loop with SP1 and ENO1 promotes IRF4-mediated myeloma progression and bone destruction
A novel mechanistic insight is introduced into the pathogenesis of myeloma and bone deterioration and disruption of the ENO1–PTTG1 interaction is identified as a potential dual-targeting therapeutic strategy, demonstrating significant efficacy in curbing myeloma progression and osteolytic lesions.